keyword
MENU ▼
Read by QxMD icon Read
search

Post metastasis treatment prostate cancer

keyword
https://www.readbyqxmd.com/read/29284672/hospice-admission-and-survival-following-18f-fluoride-pet-performed-for-evaluation-of-osseous-metastatic-disease-in-the-national-oncologic-pet-registry
#1
Ilana F Gareen, Bruce E Hillner, Lucy Hanna, Rajesh Makineni, Fenghai Duan, Anthony F Shields, Rathan M Subramaniam, Barry Siegel
We have previously reported that positron emission tomography using 18F-fluoride (NaF-PET) for assessment of osseous metastatic disease was associated with substantial changes in intended management in Medicare beneficiaries participating in the National Oncologic PET Registry (NOPR). Here, we use Medicare administrative data to examine the association between NaF-PET results and hospice claims within 180 days and 1-year survival. Methods: We classified NOPR NaF-PET results linked to Medicare claims by imaging indication [initial staging (IS); detection of suspected first osseous metastasis (FOM); suspected progression of osseous metastasis (POM); or treatment monitoring (TM)] and type of cancer (prostate, lung, breast or other)...
December 28, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29223469/oncological-and-functional-outcomes-of-elderly-men-treated-with-hifu-vs-minimally-invasive-radical-prostatectomy-a-propensity-score-analysis
#2
Paolo Capogrosso, Eric Barret, Rafael Sanchez-Salas, Igor Nunes-Silva, François Rozet, Marc Galiano, Eugenio Ventimiglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi, Xavier Cathelineau
AIM: To assess outcomes of whole gland high-intensity focused ultrasound (HIFU) as compared with minimally-invasive radical prostatectomy (MIRP) in elderly patients. MATERIALS & METHODS: Patients aged ≥70 years with, cT1-cT2 disease, biopsy Gleason score (GS) 3 + 3 or 3 + 4 and preoperative PSA ≤10 ng/mL were submitted to either whole-gland HIFU or MIRP. Propensity-score matching analysis was performed to ensure the baseline equivalence of groups. Follow-up visits were routinely performed assessing PSA and urinary function according to the International Continence Score (ICS) and the International Prostatic Symptoms Score (IPSS) questionnaires...
December 1, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29191854/intended-vs-inferred-treatment-after-18f-fluoride-pet-performed-for-evaluation-of-osseous-metastatic-disease-in-the-national-oncologic-pet-registry
#3
Bruce E Hillner, Lucy Hanna, Rajesh Makineni, Fenghai Duan, Anthony F Shields, Rathan M Subramaniam, Ilana Gareen, Barry A Siegel
We have previously reported that PET with 18F-fluoride (NaF-PET) for assessment of osseous metastatic disease led to changes in intended management in a substantial fraction of patients with prostate or other types of cancer participating in the National Oncologic PET Registry (NOPR). This study was performed to assess the concordance of intended patient management after NaF-PET and inferred management based on analysis of Medicare claims. Methods: We analyzed linked post-PET data of consenting NOPR participants age > 65 years from 2011 to 2014 and their corresponding Medicare claims...
November 30, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29063620/predictive-value-of-epithelial-mesenchymal-transition-emt-signature-and-parp-1-in-prostate-cancer-radioresistance
#4
Timothy W Stark, Patrick J Hensley, Amanda Spear, Hong Pu, Stephen S Strup, Natasha Kyprianou
INTRODUCTION: Epithelial-mesenchymal-transition (EMT) has been previously identified as a contributor to prostate cancer progression to metastasis and therapeutic resistance to antiandrogens and radiotherapy. In this study we conducted a retrospective analysis to investigate the significance of radiation-induced EMT and consequential changes to the tumor microenvironment in biochemical recurrence and response to radiotherapy in prostate cancer patients. METHODS: Expression profiling and localization for EMT effectors, E-Cadherin, N-Cadherin, β-catenin and Vimentin was assessed in human prostate tumor specimens pre- and post-radiotherapy and correlated with biochemical recurrence...
December 2017: Prostate
https://www.readbyqxmd.com/read/29039785/prospective-comparison-of-f-18-choline-pet-ct-scan-versus-axial-mri-for-detecting-bone-metastasis-in-biochemically-relapsed-prostate-cancer-patients
#5
Wouter Huysse, Frédéric Lecouvet, Paolo Castellucci, Piet Ost, Valerie Lambrecht, Carlos Artigas, Marie-Laurence Denis, Kathia De Man, Louke Delrue, Lennart Jans, Aurélie De Bruycker, Filip De Vos, Gert De Meerleer, Karel Decaestecker, Valerie Fonteyne, Bieke Lambert
We compared fluor-18 choline positron emission tomography/computed tomography (PET/CT) and axial skeleton magnetic resonance imaging (MRI) prospectively obtained for the detection of bone metastases in non-castrated patients with biochemically recurrent prostate cancer following primary treatment. PET/CT was performed 45 min post-injection of 3-4 MBq/kg F-18 methyl choline. MRI included T1- and fluid sensitive T2-weighted images of the spine and pelvis. Readers were initially blinded from other results and all scans underwent independent double reading...
October 17, 2017: Diagnostics
https://www.readbyqxmd.com/read/28916273/identification-of-recurrence-sites-following-post-prostatectomy-treatment-for-prostate-cancer-using-11-c-choline-positron-emission-tomography-and-multiparametric-pelvic-mri
#6
Avinash Nehra, William P Parker, Rimki Haloi, Sean S Park, Lance A Mynderse, Val J Lowe, Brian J Davis, J Fernando Quevedo, Geoffrey B Johnson, Eugene D Kwon, R Jeffrey Karnes
PURPOSE: To describe anatomic sites of recurrence among prostate cancer patients with biochemical recurrence following radical prostatectomy (RP) and postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT) using (11)C-Choline PET/CT and multiparametric-MRI. MATERIALS AND METHODS: RP patients evaluated with (11)C-Choline PET/CT and multiparametric-MRI following RT and/or ADT were evaluated for patterns of recurrence and clinicopathologic features...
September 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28900507/targeting-micrornas-in-prostate-cancer-radiotherapy
#7
REVIEW
Jie Ni, Joseph Bucci, Lei Chang, David Malouf, Peter Graham, Yong Li
Radiotherapy is one of the most important treatment options for localized early-stage or advanced-stage prostate cancer (CaP). Radioresistance (relapse after radiotherapy) is a major challenge for the current radiotherapy. There is great interest in investigating mechanisms of radioresistance and developing novel treatment strategies to overcome radioresistance. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression at the post-transcriptional level, participating in numerous physiological and pathological processes including cancer invasion, progression, metastasis and therapeutic resistance...
2017: Theranostics
https://www.readbyqxmd.com/read/28761588/salvage-prostatectomy-for-post-radiation-adenocarcinoma-with-treatment-effect-pathological-and-oncological-outcomes
#8
Michael J Metcalfe, Patricia Troncoso, Charles C Guo, Hsiang-Chun Chen, Yasar Bozkurt, John F Ward, Louis L Pisters
INTRODUCTION: Prostate biopsies following localized radiation therapy for prostate cancer often demonstrate residual prostatic carcinoma with treatment effect (CTE). The final oncological outcome of prostatic CTE is currently uncertain. We studied the pathological and oncological outcomes for a large cohort of patients who had CTE on post-radiation therapy biopsy and subsequently underwent salvage radical prostatectomy (SRP). METHODS: A single-centre retrospective review of all SRPs performed from 1995-2014 was performed...
July 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28760557/testicular-metastasis-from-prostatic-adenocarcinoma-presenting-as-recurrent-epididymo-orchitis
#9
Kyle M Waisanen, Tijani Osumah, Sneha S Vaish
OBJECTIVE: To present a rare case of testicular metastasis from prostatic adenocarcinoma origin and to provide a meaningful discussion of currently available supporting literature. MATERIALS AND METHODS: Pertinent health information was obtained by retrospective analysis of hospital electronic medical records. RESULTS: A 93-year-old man with history of castration-resistant prostatic adenocarcinoma presented with recurrent episodes of epididymo-orchitis with initial symptoms responsive to oral antibiotics...
July 28, 2017: Urology
https://www.readbyqxmd.com/read/28753787/in-men-with-castration-resistant-prostate-cancer-visceral-metastases-predict-shorter-overall-survival-what-predicts-visceral-metastases-results-from-the-search-database
#10
Colette A Whitney, Lauren E Howard, Edwin M Posadas, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Stephen J Freedland
BACKGROUND: Although visceral metastases (VMs) are widely recognized to portend worse prognoses compared with bone and lymph metastases in men with metastatic castration-resistant prostate cancer (mCRPC), little is known about what predicts VMs and the extent to which men with VMs do worse. OBJECTIVE: To determine whether men with VMs at initial mCRPC diagnosis have worse overall survival (OS) and identify predictors of VMs. DESIGN, SETTING, AND PARTICIPANTS: We analyzed 494 men diagnosed with castration-resistant prostate cancer post-1999 and no known metastases from five Veterans Affairs hospitals of the Shared Equal Access Regional Cancer Hospital (SEARCH) database who later developed metastases...
August 29, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28736322/clinical-outcomes-of-chemotherapy-na%C3%A3-ve-men-with-metastatic-castration-resistant-prostate-cancer-and-low-baseline-prostate-specific-antigen-treated-with-enzalutamide-vs-placebo
#11
Mary-Ellen Taplin, Andrew J Armstrong, Ping Lin, Andrew Krivoshik, De Phung, Teresa Parli, Bertrand Tombal, Tomasz M Beer
PURPOSE: Metastatic castration resistant prostate cancer with low baseline prostate specific antigen represents an early stage in the natural history of castration resistant prostate cancer progression (low volume disease), low prostate specific antigen producing disease or disease that is less dependent on androgen receptor biology (high volume disease). We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study...
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/28731148/molecular-genetics-and-targeted-therapy-of-wnt-related-human-diseases-review
#12
Masuko Katoh, Masaru Katoh
Canonical WNT signaling through Frizzled and LRP5/6 receptors is transduced to the WNT/β-catenin and WNT/stabilization of proteins (STOP) signaling cascades to regulate cell fate and proliferation, whereas non-canonical WNT signaling through Frizzled or ROR receptors is transduced to the WNT/planar cell polarity (PCP), WNT/G protein-coupled receptor (GPCR) and WNT/receptor tyrosine kinase (RTK) signaling cascades to regulate cytoskeletal dynamics and directional cell movement. WNT/β-catenin signaling cascade crosstalks with RTK/SRK and GPCR-cAMP-PKA signaling cascades to regulate β-catenin phosphorylation and β-catenin-dependent transcription...
September 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28723518/mid-term-outcomes-following-salvage-lymph-node-dissection-for-prostate-cancer-nodal-recurrence-status-post-radical-prostatectomy
#13
Fabio Zattoni, Avinash Nehra, Christopher R Murphy, Laureano Rangel, Lance Mynderse, Val Lowe, Eugene Kwon, R Jeffrey Karnes
BACKGROUND: Patients with oligometastatic prostate cancer lymph node recurrence can be treated with many options including salvage lymph node dissection (sLND). OBJECTIVE: Evaluation of outcomes of sLND and identification of clinicopathologic features in predicting further biochemical and radiological relapse after sLND for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Between November 1, 2009 and March 31, 2015, 117 patients with biochemical recurrence (BCR) after radical prostatectomy (RP) underwent sLND by a single surgeon after a standardized 11C-choline positron emission tomography/computed tomography...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28489571/analysis-of-stat3-post-translational-modifications-ptms-in-human-prostate-cancer-with-different-gleason-score
#14
Rossana Cocchiola, Donatella Romaniello, Caterina Grillo, Fabio Altieri, Marcello Liberti, Fabio Massimo Magliocca, Silvia Chichiarelli, Ilaria Marrocco, Giuseppe Borgoni, Giacomo Perugia, Margherita Eufemi
Prostate Cancer (PCa) is a complex and heterogeneous disease. The androgen receptor (AR) and the signal transducer and activator of transcription 3 (STAT3) could be effective targets for PCa therapy. STAT3, a cytoplasmatic latent transcription factor, is a hub protein for several oncogenic signalling pathways and up-regulates the expression of numerous genes involved in tumor cell proliferation, angiogenesis, metastasis and cell survival. STAT3 activity can be modulated by several Post-Translational Modifications (PTMs) which reflect particular cell conditions and may be implicated in PCa development and progression...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28477068/the-role-of-mir-130a-in-cancer
#15
REVIEW
He-da Zhang, Lin-Hong Jiang, Da-Wei Sun, Jian Li, Zhen-Ling Ji
MicroRNAs (miRs) are short and highly conserved non-coding RNAs molecules consisting of 18-25 nucleotides that regulate gene expression at post-transcriptional level by direct binding to complementary binding sites within the 3'untranslated region (3'UTR) of target mRNAs. New evidences have demonstrated that miRNAs play an important role in diverse physiological processes, including regulating cell growth, apoptosis, metastasis, drug resistance, and invasion. In chromosomes 11 and 22 of the miR-130 family, paralogous miRNA sequences, miR-130a and miR-130b are situated, respectively...
May 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28462855/benefits-of-using-stereotactic-body-radiotherapy-in-patients-with-metachronous-oligometastases-of-hormone-sensitive-prostate-cancer-detected-by-18f-fluoromethylcholine-pet-ct
#16
Esther W Bouman-Wammes, Joyce M van Dodewaard-De Jong, Max Dahele, Matthijs C F Cysouw, Otto S Hoekstra, R Jeroen A van Moorselaar, Maartje A H Piet, Hein J Verberne, Adriaan D Bins, Henk M W Verheul, Ben J Slotman, Daniela E Oprea-Lager, Alfons J M Van den Eertwegh
INTRODUCTION: For patients with oligometastatic recurrence of prostate cancer (PC), stereotactic body radiation therapy (SBRT) represents an attractive treatment option, as it is safe without major side effects. The aim of this study was to investigate the impact of SBRT in delaying the start of androgen deprivation therapy (ADT). PATIENTS AND METHODS: Forty-three patients treated with SBRT for oligometastatic recurrence (< 5 metastases) of hormone-sensitive PC, defined with [(18)F]fluoromethylcholine positron emission tomography/computed tomography were included...
March 29, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28063191/salvage-high-intensity-focused-ultrasound-hifu-for-locally-recurrent-prostate-cancer-after-failed-radiation-therapy-multi-institutional-analysis-of-418-patients
#17
MULTICENTER STUDY
Sebastien Crouzet, Andreas Blana, Francois J Murat, Gilles Pasticier, Stephen C W Brown, Giario N Conti, Roman Ganzer, Olivier Chapet, Albert Gelet, Christian G Chaussy, Cary N Robertson, Stefan Thuroff, John F Ward
OBJECTIVE: To report the oncological outcome of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after external beam radiotherapy (EBRT) from a multicentre database. PATIENTS AND METHODS: This retrospective study comprises patients from nine centres with local recurrent disease after EBRT treated with S-HIFU from 1995 to 2009. The biochemical failure-free survival (bFFS) rate was based on the 'Phoenix' definition (PSA nadir + 2 ng/mL)...
June 2017: BJU International
https://www.readbyqxmd.com/read/27862841/the-ubiquitin-ligase-ube4a-inhibits-prostate-cancer-progression-by-targeting-interleukin-like-emt-inducer-ilei
#18
Yanan Sun, Xiaopeng Jia, Qiang Gao, Xing Liu, Lianguo Hou
Epithelial to mesenchymal transition (EMT) is an important prerequisite for metastasis to secondary organs. Interleukin-like EMT inducer (ILEI) protein has been shown to translationally upregulated during EMT and metastatic progression as a consequence of aberrant TGF-β signaling. Our initial evaluation of FAM3C (encoding ILEI) and ILEI expression in normal prostate (PCS-440-010) and prostate cancer cell lines (DU145, LNCaP, and PC3) revealed detectable protein expression in only LNCaP cell line even though all cell lines tested had comparable FAM3C expression...
January 2017: IUBMB Life
https://www.readbyqxmd.com/read/27770303/cabazitaxel-for-hormone-relapsed-metastatic-prostate-cancer-previously-treated-with-a-docetaxel-containing-regimen-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#19
REVIEW
Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham, M Satish Kumar
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures cabazitaxel (Jevtana(®), Sanofi, UK) to submit evidence for the clinical and cost effectiveness of cabazitaxel for treatment of patients with metastatic hormone-relapsed prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
April 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/27743920/development-and-validation-of-a-24-gene-predictor-of-response-to-postoperative-radiotherapy-in-prostate-cancer-a-matched-retrospective-analysis
#20
Shuang G Zhao, S Laura Chang, Daniel E Spratt, Nicholas Erho, Menggang Yu, Hussam Al-Deen Ashab, Mohammed Alshalalfa, Corey Speers, Scott A Tomlins, Elai Davicioni, Adam P Dicker, Peter R Carroll, Matthew R Cooperberg, Stephen J Freedland, R Jeffrey Karnes, Ashley E Ross, Edward M Schaeffer, Robert B Den, Paul L Nguyen, Felix Y Feng
BACKGROUND: Postoperative radiotherapy has an important role in the treatment of prostate cancer, but personalised patient selection could improve outcomes and spare unnecessary toxicity. We aimed to develop and validate a gene expression signature to predict which patients would benefit most from postoperative radiotherapy. METHODS: Patients were eligible for this matched, retrospective study if they were included in one of five published US studies (cohort, case-cohort, and case-control studies) of patients with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherapy) and had gene expression analysis of the tumour, with long-term follow-up and complete clinicopathological data...
November 2016: Lancet Oncology
keyword
keyword
63429
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"